
Richard Krugman to Chair AAMC



Richard Krugman

Richard D. Krugman, MD, dean of the University of Colorado School of Medicine, has been selected to chair the Association of American Medical Colleges (AAMC).

Krugman will sit on the AAMC's executive committee, which serves on behalf of the AAMC executive council and acts on matters requiring immediate action. The AAMC is a nonprofit association of medical schools, teaching hospitals, and academic societies dedicated to improving health by improving the effectiveness of academic medicine.

Krugman has previously served as chair of the AAMC Council of Deans. He

has served as dean of the University of Colorado School of Medicine since March 1, 1992, after serving as acting dean for almost 2 years. A professor of pediatrics, Krugman also served from 1981 to 1992 as director of the C. Henry Kempe National Center for the Prevention and Treatment of Child Abuse and Neglect, where he gained international prominence in the field of child abuse treatment and prevention.

A graduate of Princeton University, Krugman earned his medical degree from New York University School of Medicine. He completed his internship and residency in pediatrics at the University of Colorado School of Medicine.

Thomas Ellenberger to Lead Biochemistry and Molecular Biophysics



Thomas Ellenberger (Photo by Liza Greene)

Thomas Ellenberger, DVM, PhD, has been selected as the Raymond H. Wittcoff Professor and head of the Department of Biochemistry and Molecular Biophysics at Washington University School of Medicine in St. Louis (WUSTL) effective January 1, 2006. Ellenberger comes to the University from Harvard Medical School, where he was the Hsein Wu and Daisy Yen Wu Professor of Biological Chemistry and Molecular Pharmacology.

Ellenberger succeeds Carl Frieden, PhD, who had led that department since 1996, and will direct the WUSTL BioMed 21 initiative, which calls for "converting knowledge of the genetic blueprint into practical applications." Integral to the School of Medicine's ability to attract Ellenberger was a \$6 million grant from the Danforth Foundation, which established an endowment in the support of the mission of the Bio-Med 21 initiative. Ellenberger is known for his pioneering research elucidating the structures of proteins that replicate deoxyribonucleic acid (DNA) or repair DNA damage and thereby ensure faithful transmission of the genetic blueprint from generation to generation.

Ellenberger's research has studied the body's normal defenses against diseaseproducing mutations and the molecular bases of inherited diseases that cause chromosomal instability or cancer. Next he hopes to target those processes for the development of selective antibiotics and other treatments of infectious diseases.

Ellenberger received his doctorate in pharmacology from Harvard Medical School in 1989. Prior to his studies at Harvard, he earned a doctorate in veterinary medicine from the Iowa State University College of Veterinary Medicine.